Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI plus cetuximab with dermal prophylaxis in first-line metastatic colorectal cancer
2010-019885-10Phase 4Completed
- Sponsor
- University Medical Center Mainz
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by University Medical Center Mainz. Primary endpoint: Progression-free survival (PFS) rate at 1 year. Started Oct 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-019885-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019885-10.